title: Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis.
abstract: BACKGROUND
  Basic fibroblast growth factor (bFGF) is known to stimulate angiogenesis and thus to influence the proliferation, migration and survival of tumor cells. Many studies examined the relationship between human bFGF overexpression and survival in lung cancer patients, but the results have been mixed. To systematically summarize the clinical prognostic function of bFGF in lung cancer, we performed this systematic review with meta-analysis.
  
  
  METHODS
  Studies were identified by an electronic search of PubMed, EMBASE, China National Knowledge Infrastructure and Wanfang databases, including publications prior to August 2014. Pooled hazard ratios (HR) for overall survival (OS) were aggregated and quantitatively analyzed by meta-analysis.
  
  
  RESULTS
  Twenty-two studies (n = 2154) were evaluated in the meta-analysis. Combined HR suggested that bFGF overexpression had an adverse impact on survival of patients with lung cancer(HR = 1.202,95%CI, 1.022-1.382). Our subgroup analysis revealed that the combined HR evaluating bFGF expression on OS in operable non-small cell lung cancer (NSCLC) was 1.553 (95%CI, 1.120-1.986); the combined HR in small cell lung cancer (SCLC) was 1.667 (95%CI, 1.035-2.299). There was no significant impact of bFGF expression on survival in advanced NSCLC.
  
  
  CONCLUSIONS
  This meta-analysis showed that bFGF overexpression is a potential indicator of worse prognosis for patients with operable NSCLC and SCLC, but is not associated with outcome in advanced NSCLC. The data suggests that high bFGF expression is highly related to poor prognosis. Nevertheless,more high-quality studies should be performed in order to provide additional evidence for the prognostic value of bFGF in lung cancer.
authors.affiliation: Department of General Medicine, Beijing Tuberculosis and Thoracic tumor research Institute/ Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
authors.forename: Mingming
authors.initials: M
authors.lastname: Hu
authors.affiliation: Department of General Medicine, Beijing Tuberculosis and Thoracic tumor research Institute/ Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Department of General Medicine, Beijing Tuberculosis and Thoracic tumor research Institute/ Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
authors.forename: Jiabei
authors.initials: J
authors.lastname: He
authors.affiliation: Department of General Medicine, Beijing Tuberculosis and Thoracic tumor research Institute/ Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
authors.forename: Baolan
authors.initials: B
authors.lastname: Li
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D044466:Asian People; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D016222:Fibroblast Growth Factor 2 / Q000235:genetics*; D015870:Gene Expression; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D016016:Proportional Hazards Models; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D044465:White People
chemical_list: D000970:Antineoplastic Agents; D016222:Fibroblast Growth Factor 2
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1190-9
references.pmid: 21224376
references.citation: Endocrinology. 2011 Nov;152(11):4232-41
references.pmid: 21914781
references.citation: Eur Cytokine Netw. 2009 Dec;20(4):225-34
references.pmid: 20167562
references.citation: Trials. 2007 Jun 07;8:16
references.pmid: 17555582
references.citation: Int J Biochem Cell Biol. 2000 Mar;32(3):263-7
references.pmid: 10716624
references.citation: Crit Rev Oncol Hematol. 2012 Nov;84(2):149-60
references.pmid: 22494932
references.citation: Syst Rev. 2013;2:10
references.pmid: 23379753
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6006-11
references.pmid: 19826110
references.citation: Lung Cancer. 2011 Sep;73(3):366-74
references.pmid: 21333372
references.citation: Cancer Res. 2009 Nov 15;69(22):8645-51
references.pmid: 19903855
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1407-12
references.pmid: 18316562
references.citation: Iowa Orthop J. 2012;32:150-63
references.pmid: 23576936
references.citation: Eur J Cancer. 1996 Aug;32A(9):1504-9
references.pmid: 8911109
references.citation: Pol J Pathol. 2012 Mar;63(1):1-7
references.pmid: 22535614
references.citation: Front Physiol. 2014 Mar 05;5:75
references.pmid: 24634660
references.citation: Lung Cancer. 2002 Jul;37(1):57-63
references.pmid: 12057868
references.citation: Eur J Cardiothorac Surg. 2004 Mar;25(3):443-8
references.pmid: 15019676
references.citation: Lung Cancer. 2001 Feb-Mar;31(2-3):213-9
references.pmid: 11165400
references.citation: Thromb Haemost. 2010 Nov;104(5):875-85
references.pmid: 20886177
references.citation: BMB Rep. 2012 May;45(5):287-92
references.pmid: 22617452
references.citation: Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):36-41
references.pmid: 15796880
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):6014-22
references.pmid: 18829480
references.citation: Cancer. 2002 Feb 15;94(4):1083-93
references.pmid: 11920479
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1492-5
references.pmid: 12433733
references.citation: Exp Lung Res. 2010 Nov;36(9):531-7
references.pmid: 20939760
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):442-7
references.pmid: 20950963
references.citation: J Natl Cancer Inst. 1990 Jan 3;82(1):4-6
references.pmid: 1688381
references.citation: Anticancer Res. 1998 Mar-Apr;18(2A):1123-7
references.pmid: 9615776
references.citation: Br J Cancer. 2001 Nov 30;85(11):1706-12
references.pmid: 11742492
references.citation: Eur Respir J. 2001 Oct;18(4):705-19
references.pmid: 11716177
references.citation: J Thorac Oncol. 2014 Jun;9(6):848-55
references.pmid: 24807156
references.citation: Acta Biochim Biophys Sin (Shanghai). 2008 Apr;40(4):297-303
references.pmid: 18401527
references.citation: Nat Rev Cancer. 2010 Feb;10(2):116-29
references.pmid: 20094046
references.citation: Clin Lung Cancer. 2012 Mar;13(2):90-5
references.pmid: 21959109
references.citation: Lab Invest. 2012 Feb;92(2):214-23
references.pmid: 21946856
references.citation: Nat Rev Drug Discov. 2009 Mar;8(3):235-53
references.pmid: 19247306
references.citation: Med Oncol. 2004;21(3):241-50
references.pmid: 15456951
references.citation: J Thorac Oncol. 2009 May;4(5):578-85
references.pmid: 19318994
references.citation: Cancer Res. 2002 Sep 15;62(18):5210-7
references.pmid: 12234986
references.citation: Oncol Rep. 2002 Jan-Feb;9(1):119-23
references.pmid: 11748468
references.citation: Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14389-94
references.pmid: 9826710
references.citation: Mol Cancer Res. 2013 Dec;11(12):1585-96
references.pmid: 24092775